Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thx for posting. growth still very limited. I just don't get it: why not massively extend the go to market and boost the sales force?
I might have missed it: how is the revenue split in the last ER: how much in the US, how much Europe, how much RoW? Are those numbers known?
and what's even worse: no one on their managent team has a proven track record in building up and execute a successful go to market in europe. it's an entierly different ball park wether you work for big pharma and had to introduce new products with your well known brand (aka merck or other BP). or wether you try to do so - relatively speaking - with an unknown product of an unknown company. i consider GIA a strategic nightmare.
very well said, i couldn't agree more with your opinion.
Swissquote, anyone? struggling to get my proxyvote numbers from them, would appreciate to get informations how to handle those guys.
marjac, i would like to be included as well. heavy losses, probabky somewhere close to captbeers area. email: stance150@gmail.com
thx a lot & best regards
I wonder the impact on the share price once the China decision (hopefully approval with broad label)comes out. Only very few days left until the end of 2021 - I hope AMRN conviction to have it done at latest by year's end (2021...) doesn't turn out to have been too optimistic. And then, how to address the huge chinese market - I would love if mgmt would shed some light on their targets/forecasts, plans and activities.
generally speaking yes, I agree, it's a good sign. But with this transactions totalling 12'000 shares - for such a guy with probably deep pockets that doesn't look like someone who is fully convinced...
Thanks, well written overview regarding the process and it's (hopefully likely) timelines.
Patience is needed, although I would love to see a fast track.
I go for $13.50.
I'm just wondering, how many of all those posters here have top notch and successful top management experience. It's very easy to blame JT regarding the current stock performance, but unfortunately that doesn't help to turn the ship. And we can discuss about the lost lawsuit a thousand times and always come up with the very simple answer (according to all the posts as well as alls the analyst's and patent specialist's comments know to me): it took everybody completely by surprise. It like a "expect the unexpected", one of those black swans
ignored, not worth spending time reading.
Well said, couldn't agree more, thanks for posting your clear statement.
+ 1, fully agree
well said. I fully agree with you. as a (very) long time holder for approx 7 year, I've been through many ups & downs. I heavily appreciate the performance of the management team. And I'm am confident that's it's still the right team for next steps at Amarin.
Guys, sorry for the confusion.
Pixelplus made approx 40 Mio USD revs and approx 9 Mio profit in fiscal 2011. Souce: etnews.com as well as a report from dun & bradstreet from june 2012.
Well, well, let's see.
Figures for fiscal 2011 were just too promising. Published end of march 2012 in etnews.com
PIXELPLUS anyone still following the company after the delisting in the US by the end of february? any news regarding re-listing in South Korea or financials for 2012?
hi dave
do you still hold on to this shares (adr's)?
ambiente
hi there, anyone still holding the ADS?
results for fiscal 2011 were a blast: approx 50 mio revenues and earnings approx 12 mio (all in usd). wonder the next steps regarding relisting in south korea.
are there any news?